UNIVERSITY OF LEEDS

This is a repository copy of Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/169834/

Version: Accepted Version

Article:

Ager, M, Njoku, K, Serra, M et al. (12 more authors) (2020) Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU International. ISSN 1464-4096

https://doi.org/10.1111/bju.15309

© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Ager, M, Njoku, K, Serra, M et al. (12 more authors) (2020) Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU International. ISSN 1464-4096, which has been published in final form at http://doi.org/10.1111/bju.15309. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown


If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/ Figures 1 to 4:

Figure 1: Outcomes of patients deemed suitable for adjuvant radiotherapy. RT=

radiotherapy.








Figure 3: Cancer specific survival (CSS) (n = 125)




Figure 4: Overall survival (OS) (n = 125)




Figure 5: Overall survival (OS) Chemosensitization vs No chemosensitization (n =

125) (p = 0.065)

